TipRanks
Protagonist Therapeutics (DE:PGF)
BERLIN:PGF
Germany Market
PGF
Protagonist Therapeutics
RESEARCH TOOLSreports

Protagonist Therapeutics (PGF) Stock News & Sentiment

1 Followers
Protagonist Therapeutics: Buy Rating Reiterated as Mimrylo Approval De-Risks Lead Asset; $186 Price Target Unchanged
Premium
Ratings
Protagonist Therapeutics: Buy Rating Reiterated as Mimrylo Approval De-Risks Lead Asset; $186 Price Target Unchanged
18d ago
PTGX
Protagonist Therapeutics: Rusfertide Approval and Partnered Pipeline Underpin Buy Rating, $173 Price Target Reaffirmed
Premium
Ratings
Protagonist Therapeutics: Rusfertide Approval and Partnered Pipeline Underpin Buy Rating, $173 Price Target Reaffirmed
20d ago
PTGX
Protagonist Therapeutics: Emerging Multi-Asset Revenue Streams and Robust Pipeline Drive Buy Rating Ahead of Rusfertide Approval
Premium
Ratings
Protagonist Therapeutics: Emerging Multi-Asset Revenue Streams and Robust Pipeline Drive Buy Rating Ahead of Rusfertide Approval
1M ago
PTGX
Protagonist Therapeutics: Diversified Pipeline Progress and Strong Cash Position Drive Buy Rating and Price Target Hike from $130 to $175
Premium
Ratings
Protagonist Therapeutics: Diversified Pipeline Progress and Strong Cash Position Drive Buy Rating and Price Target Hike from $130 to $175
1M ago
PTGX
Protagonist Therapeutics Highlights ICOTYDE Launch and Rusfertide Deal
Premium
Company Announcements
Protagonist Therapeutics Highlights ICOTYDE Launch and Rusfertide Deal
2M ago
8K
PTGX
PTGX’s PN-881 Phase 1 Completion: A Quiet Milestone With Big Pipeline Implications
Premium
Company Announcements
PTGX’s PN-881 Phase 1 Completion: A Quiet Milestone With Big Pipeline Implications
2M ago
PTGX
Analyst Tara Bancroft Boosts Protagonist Therapeutics Price Target to $155 on Stronger Icotyde Royalty Outlook and Buy Rating
Premium
Ratings
Analyst Tara Bancroft Boosts Protagonist Therapeutics Price Target to $155 on Stronger Icotyde Royalty Outlook and Buy Rating
2M ago
PTGX
More DE:PGF News >

PGF News on the Web

Protagonist (PTGX) Swings To A Profit As Two Drugs Near Blockbuster Status
Insider Monkey
Neutral
Protagonist Therapeutics price target raised to $190 from $178 at BMO Capital
TipRanks News
Bullish
Protagonist Therapeutics price target raised to $180 from $153 at Barclays
TipRanks News
Bullish
Analysts Are Bullish on These Healthcare Stocks: Ascendis Pharma (ASND), Protagonist Therapeutics (PTGX)
TipRanks News
Bullish
Analysts Are Bullish on Top Healthcare Stocks: Palvella Therapeutics (PVLA), Protagonist Therapeutics (PTGX)
TipRanks News
Bullish
Protagonist Therapeutics price target raised to $182 from $175 at Citi
TipRanks News
Bullish
Protagonist Therapeutics price target raised to $170 from $165 at Citizens
TipRanks News
Bullish
Protagonist Therapeutics: Rusfertide Approval and Partnered Pipeline Underpin Buy Rating, $173 Price Target Reaffirmed
TipRanks News
Bullish

News Score - Last 7 Days

Neutral
DE:PGF
Sector Average
Media Buzz
This Week1 articles
Weekly Average6.25 articles
News Sentiment
This Week50%
Sector Average91%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is DE:PGF’s Media Buzz Sentiment?
1 articles about DE:PGF were published this week. In an average week, 6.25 articles are published.
    What is DE:PGF’s weekly average amount of articles?
    In an average week, 6.25 articles about DE:PGF are published.
      What is DE:PGF’s News Sentiment?
      50% of articles about DE:PGF were positive this week, compared to its sector average of 91%.
        Healthcare Stocks that are Trending in the News
        CRLCharles River Labs
        DFTXDefinium Therapeutics
        AMRXAmneal Pharmaceuticals
        SMMTSummit Therapeutics
        ABEOAbeona Therapeutics
        Showing the stocks with the most bullish news sentiment over the past week